Preserve the US interchangeable standard that has helped drive physician and patient confidence in biosimilars

Author(s): Michael S Reilly, Esq

Abstract: The US Food and Drug Administration (FDA) proposed eliminating the distinction between biosimilars and interchangeable biosimilars with the stated aim of aligning with European policy and enhance biosimilar uptake. However, this move is misguided as it would result in widespread generic-style automatic substitution at the pharmacy level; which is rare in Europe. Physician confidence […]

Read more →